research THERAPEUTIC EVALUATION OF ḤIJAMAH BIL SHART IN QILLAT SH'AR (ANDROGENETIC ALOPECIA): A CASE STUDY WITH UNANI AND BIOMEDICAL INSIGHTS
Wet cupping may improve hair health in androgenetic alopecia without side effects.
Search
for
Sort by
Research
990-1000 / 1000+ results 
research Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α-reductase
Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
research Skin and metabolic syndrome: A review of the possible associations
Certain medications can impact metabolic syndrome, with some improving conditions like high blood sugar and others having no effect.
research A Disease-Modifying Approach for Advanced Hidradenitis Suppurativa (Regimen with Metformin, Liraglutide, Dapsone, and Finasteride): A Case Report
Combination therapy helped patient with advanced Hidradenitis Suppurativa achieve remission.
research A review of acitretin, a systemic retinoid for the treatment of psoriasis
Acitretin is effective for certain types of psoriasis, safe for long-term use, and often combined with other treatments.
research Preventive and Therapeutic Efficacy of Finasteride and Dutasteride in TRAMP Mice
Dutasteride works better than finasteride for preventing and treating prostate cancer.
research Long-term Oral Administration of 5α-reductase Inhibitor Attenuates Erectile Function by Inhibiting Autophagy and Promoting Apoptosis of Smooth Muscle Cells in Corpus Cavernosum of Aged Rats
Long-term use of a certain medication can worsen erectile function in aged rats by damaging penile muscle cells.
research Unusual Anti-Angiogenic Effect of Combined Hormonal Blockade
research Characteristics and predictive values of super-responders in alopecia areata under tofacitinib treatment: A single-center retrospective study
Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.